MedPath

Changes in Renal Function and Body Composition in Pulmonary Hypertension

Completed
Conditions
Pulmonary Hypertension
Renal Function Abnormal
Interventions
Diagnostic Test: No intervention
Registration Number
NCT03039972
Lead Sponsor
University of Giessen
Brief Summary

Changes in renal function and body composition in patients with pulmonary hypertension

Detailed Description

This prospective single-center study is designed to analyze changes in renal function and body composition in patients with suspected or pre-diagnosed pulmonary hypertension at pulmonary hypertension outpatient clinic, University Hospital Giessen and Marburg, Campus Giessen.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
500
Inclusion Criteria
  • Subjects older than 18 years at pulmonary hypertension outpatient clinic
  • Subjects who signed informed consent forms
Exclusion Criteria
  • Patients refusing to participate or withdraw consent during follow-up

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Pulmonary HypertensionNo interventionAdult outpatients with suspected or prediagnosed pulmonary hypertension irrespective of subclass and all chronic kidney disease stages
Primary Outcome Measures
NameTimeMethod
Changes in renal function in patients with pulmonary hypertension1 year

Estimated GFR based on Chronic Kidney Disease Epidemiology Collaboration-creatinine-cystatin C will be used to determine renal function at baseline and at 1 year follow-up

Secondary Outcome Measures
NameTimeMethod
Changes in nutritional status in patients with pulmonary hypertension1 year

Bioimpedance analysis will be used to determine lean tissue and fat mass at baseline and at 1 year follow-up

Changes in hydration status in patients with pulmonary hypertension1 year

Bioimpedance analysis will be used to determine hydration status at baseline and at 1 year follow-up

Prognostic value of baseline renal function, hydration and nutritional status on pulmonary hypertension-associated morbidity and mortality1 year

pulmonary hypertension-associated morbidity and mortality (defined as escalation of pulmonary hypertension-specific therapy, unscheduled hospitalization and all-cause mortality) will be prospectively assessed during follow-up period

Trial Locations

Locations (1)

University Clinic Giessen and Marburg - Campus Giessen

🇩🇪

Giessen, Hessen, Germany

© Copyright 2025. All Rights Reserved by MedPath